Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Non-del(5q) transfusion-dependent low/intermediate-1 myelodysplastic syndrome (MDS) patients achieve an erythroid response with lenalidomide in 25% of cases. Addition of an erythropoiesis-stimulating agent could improve response rate. The impact of recurrent somatic mutations identified in the disea...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Chesnais, Virginie, Renneville, Aline, Toma, Andrea, Lambert, Jérôme, Passet, Marie, Dumont, Florent, Chevret, Sylvie, Lejeune, Julie, Raimbault, Anna, Stamatoullas, Aspasia, Rose, Christian, Beyne-Rauzy, Odile, Delaunay, Jacques, Solary, Eric, Fenaux, Pierre, Dreyfus, François, Preudhomme, Claude, Kosmider, Olivier, Fontenay, Michaela
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2016
Teme:
Myeloid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4937206/
https://ncbi.nlm.nih.gov/pubmed/26626993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-04-640128
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items